U Bender1, Y S Rho2, I Barrera1, S Aghajanyan1, J Acoba2,3, P Kavan1. 1. Gerald Bronfman Department of Oncology, McGill University Faculty of Medicine, Montreal, QC. 2. University of Hawaii Internal Medicine Program, Honolulu, HI, U.S.A. 3. University of Hawaii Cancer Center, Honolulu, HI, U.S.A.
Abstract
Background: To date, the role of adjuvant systemic therapy in stages ii and iii colon cancer remains a topic of interest and debate. The objective of the present review was to assess the most recent data, specifically addressing methods of risk stratification, duration of therapy, and future directions. Methods: PubMed and medline were searched for literature pertinent to adjuvant chemotherapy in either stage ii or stage iii colorectal cancer. Summary: Locoregional disease, histopathology, age, laterality, and a number of other biologic and molecular markers appear to have a role in disease risk stratification. The duration of adjuvant therapy for stage iii disease can vary based on risk factors, but use of adjuvant therapy and duration of therapy in stage ii disease remain controversial. Future directions should include genomic assays and improved study design to provide concrete evidence about the duration of adjuvant folfox or capox and about other types of chemotherapy and immunotherapy. 2019 Multimed Inc.
Background: To date, the role of adjuvant systemic therapy in stages ii and iii colon cancer remains a topic of interest and debate. The objective of the present review was to assess the most recent data, specifically addressing methods of risk stratification, duration of therapy, and future directions. Methods: PubMed and medline were searched for literature pertinent to adjuvant chemotherapy in either stage ii or stage iii colorectal cancer. Summary: Locoregional disease, histopathology, age, laterality, and a number of other biologic and molecular markers appear to have a role in disease risk stratification. The duration of adjuvant therapy for stage iii disease can vary based on risk factors, but use of adjuvant therapy and duration of therapy in stage ii disease remain controversial. Future directions should include genomic assays and improved study design to provide concrete evidence about the duration of adjuvant folfox or capox and about other types of chemotherapy and immunotherapy. 2019 Multimed Inc.
Authors: Aimery de Gramont; Eric Van Cutsem; Hans-Joachim Schmoll; Josep Tabernero; Stephen Clarke; Malcolm J Moore; David Cunningham; Thomas H Cartwright; J Randolph Hecht; Fernando Rivera; Seock-Ah Im; György Bodoky; Ramon Salazar; Frédérique Maindrault-Goebel; Einat Shacham-Shmueli; Emilio Bajetta; Martina Makrutzki; Aijing Shang; Thierry André; Paulo M Hoff Journal: Lancet Oncol Date: 2012-11-16 Impact factor: 41.316
Authors: M Ychou; J-L Raoul; J-Y Douillard; S Gourgou-Bourgade; R Bugat; L Mineur; F Viret; Y Becouarn; O Bouché; E Gamelin; M Ducreux; T Conroy; J-F Seitz; L Bedenne; A Kramar Journal: Ann Oncol Date: 2009-01-29 Impact factor: 32.976
Authors: Amy J French; Daniel J Sargent; Lawrence J Burgart; Nathan R Foster; Brian F Kabat; Richard Goldberg; Lois Shepherd; Harold E Windschitl; Stephen N Thibodeau Journal: Clin Cancer Res Date: 2008-06-01 Impact factor: 12.531
Authors: T T Seppälä; J P Böhm; M Friman; L Lahtinen; V M J Väyrynen; T K E Liipo; A P Ristimäki; M V J Kairaluoma; I H Kellokumpu; T H I Kuopio; J-P Mecklin Journal: Br J Cancer Date: 2015-05-14 Impact factor: 7.640
Authors: Rene Warschkow; Michael C Sulz; Lukas Marti; Ignazio Tarantino; Bruno M Schmied; Thomas Cerny; Ulrich Güller Journal: BMC Cancer Date: 2016-07-28 Impact factor: 4.430
Authors: Eva Parisi; Anabel Sorolla; Robert Montal; Rita González-Resina; Anna Novell; Antonieta Salud; Maria Alba Sorolla Journal: Cancers (Basel) Date: 2020-11-11 Impact factor: 6.639
Authors: André Fonseca; Sara Ventura Ramalhete; André Mestre; Ricardo Pires das Neves; Ana Marreiros; Pedro Castelo-Branco; Vânia Palma Roberto Journal: Aging (Albany NY) Date: 2021-09-21 Impact factor: 5.682